A diabetes drug taken for weight loss could help spare millions from knee surgery. New analysis of medical records shows that GLP-1 receptor agonists—particularly the newer agents semaglutide and tirzepatide—are linked to significantly lower rates of knee replacement surgery in people with osteoarthritis, a finding that opens unexpected possibilities for slowing a condition that affects more than 300 million people worldwide.
The research, published in Regional Anesthesia & Pain Medicine, matters because osteoarthritis is a progressive disease with no effective disease-modifying medications currently available. Many patients eventually need knee replacement surgery, though not everyone is eligible for the procedure. As obesity rates rise and populations age, osteoarthritis prevalence is expected to climb alongside these trends. Finding a way to slow the condition's progression—or prevent it from reaching the point where surgery becomes necessary—could transform how millions manage this chronic pain.
Researchers drew on anonymized data from the TriNetX Global Research Network to examine adults diagnosed with knee osteoarthritis between January 2010 and December 2024. They compared patients treated with GLP-1 receptor agonists to untreated osteoarthritis patients with similar age, sex, race, weight, and health profiles. The analysis tracked 28,599 patients treated with newer-generation GLP-1 drugs for one year, 13,351 treated for three years, and larger groups across all GLP-1 classes over both timeframes. Crucially, the researchers assessed knee replacement surgery rates at one, three, five, and eight years after diagnosis.
The results were consistent across all time points: treatment was associated with fewer knee replacements than in the comparison group. One year of any GLP-1 receptor agonist reduced the cumulative risk of knee replacement by 1.4 percentage points at three years, climbing to nearly three percentage points by year eight. But the biggest impact came from sustained use of the newest drugs: three years of treatment with semaglutide or tirzepatide cut the cumulative risk by nearly five percentage points at the eight-year mark—a meaningful reduction for a condition affecting so many people.
How do these drugs work? While the exact mechanism remains under investigation, evidence suggests GLP-1 receptor agonists may reduce inflammation and protect cartilage from further damage, potentially slowing osteoarthritis progression itself rather than just masking symptoms. This possibility explains the growing excitement around repurposing these medications beyond diabetes and weight management.
The researchers emphasize important caveats. The study relied on prescription data without confirmation that patients actually took the drugs consistently. Unmeasured factors—frailty, physical activity levels, functional capacity, and osteoarthritis severity—weren't accounted for in the analysis. "These findings should be interpreted as observational associations consistent with potential disease-modifying effects rather than evidence of causality," the researchers wrote, signaling that more rigorous research is needed.
Still, the findings suggest a compelling possibility: GLP-1 receptor agonists may offer a complementary, non-surgical approach for managing knee osteoarthritis in eligible patients, particularly those living with obesity or metabolic disease. As obesity and aging drive osteoarthritis rates upward, a medication that might slow progression or defer surgery could ease suffering for millions.